辛伐他汀对急性冠状动脉综合症患者血脂和高敏C反应蛋白的影响  

The effect of simvastatin on serum level of blood lipid and high sensitivity C-reactive protein in patients with acute coronary syndromes

作　　者：佘贵平 邹胜华[1] 贺志明[1] 刘友新[1] 

机构地区：[1]邵阳医学高等专科学校附属医院心内科,湖南邵阳422000

出　　处：《国际医药卫生导报》2005年第17期119-121,共3页International Medicine and Health Guidance News

摘　　要：目的探讨辛伐他汀对急性冠状动脉综合症(ACS)患者血脂、高敏C反应蛋白(hsCRP)的影响。方法80例ACS患者,并选择30例健康人作为对照。采用双盲、随机、对照方法分为治疗组40例(口服辛伐他汀20mg、QN、2月)和对照组40例(未服辛伐他汀,其余同治疗组);于治疗前后分别测定血桨总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL)、高密度脂蛋白胆固醇(HDL)、hsCRP、白介素6(IL-6)。结果ACS组与健康对照组之间hsCRP、IL-6、血脂之间比较差异有统计学意义,辛伐他汀治疗组与对照组治疗后血清hsCRP、IL-6之间血脂比较差异有统计学意义,辛伐他汀治疗组与对照组的死亡和心血管事件发生率比较差异有统计学意义。结论血清hsCRP、IL-6的升高与粥样斑块的破裂明显相关。辛伐他汀可降低ACS患者血清hsCRP、IL-6的水平,从而起到减轻炎症反应、稳定斑块的作用。Objective To explore the effect of simvastatin on the serum levels of high sensitivity Creactive protein（hsCRP） and interleukin 6 and blood lipid in the patients with acute cornary syndromes （ACS）.Methods Eighty patients with ACS were studied , At the same time, 30 cases healthy individuals were selected as a control. 80 patients with ACS were stratified by randomized, double blind, contrastive assigned to simvastatin group（20mg/d of simvastatin for 8 weeks, n=40） or to the control group（no lipid-lowing drugs, n-40）. The serum levels of hsCRP, IL-6, TC, TG, LDL-C, HDL C before and after treatment were detected. Results There was significant difference in serum level of hsCRP , IL-6 and blood lipid among ACSgroup and control group, The serum level of hsCRP, IL-6 and blood lipid were different between simvastatin, treatment group and control group. Conclusions Plaque disruption may be related to the increased serum of hsCRP and IL-6. simvastatin can decrease serum level of hsCRP AND IL-6 and blood lipid in patients with ACS which may decreased inflammatory reaction and have effect on plaque stabilization

关 键 词：脂类和降血脂药 急性冠状动脉综合症 C反应蛋白 白介素-6 高敏C反应蛋白 辛伐他汀 血脂 患者 低密度脂蛋白胆固醇 高密度脂蛋白胆固醇 

分 类 号：R541.4[医药卫生—心血管疾病]